Takhzyro denied for missing prior authorization by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for takhzyro are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Requires Prior Authorization for Takhzyro — and How to Get It Approved

Prior-authorization (PA) denials for Takhzyro (lanadelumab) typically occur because the initial PA request was submitted without sufficient clinical documentation, or the submitted information did not map clearly to UHC's approval criteria for HAE prophylaxis. A PA denial is not a final determination — it is the beginning of the appeals process.

Most PA denials for specialty drugs like Takhzyro are overturned when a complete, criteria-matched documentation package is submitted on appeal. The key is to obtain UHC's exact policy criteria and answer each one with a specific chart fact.

## Federal Appeal Rights

• ACA §2719 / ERISA §503 guarantee the right to appeal a PA denial through internal review and, if denied, independent external review.
• Internal appeal deadline: 180 days from the denial notice.
• External review window: approximately 4 months after final internal denial.
• Expedited review (72-hour decision) is appropriate given the risk of laryngeal or other life-threatening HAE attacks — document this urgency explicitly.

## Appeal Timeline

1. Obtain the denial notice and the PA criteria UHC applied (request the operative coverage policy in writing). 2. Have your prescriber gather all required clinical documentation. 3. File a written internal appeal with a complete documentation package. 4. UHC must decide within 30 days (standard) or 72 hours (expedited). 5. If denied, file for external IRO review immediately.

## Documentation to Gather

• Diagnosis confirmation: Genetic testing or laboratory report confirming HAE type and severity.
• Attack history: Documented log of HAE attack frequency, anatomical locations, severity, and any emergency or hospital encounters in the prior 6–12 months.
• Prior treatment history: Names, dates, and documented outcomes for all prior acute and prophylactic HAE treatments, including reasons for discontinuation or inadequate response.
• Clinical severity: Treating physician's chart notes on disease burden, quality-of-life impact, and medical risk.
• Prescriber medical-necessity letter: A detailed letter from a physician with HAE expertise (allergist/immunologist or relevant specialist) explaining the clinical rationale for Takhzyro specifically, referencing applicable professional guideline organization recommendations.
• Prescriber specialty confirmation: Documentation of the prescribing physician's specialty if UHC requires specialist prescribing for approval.

## Criteria-Mapping Structure

Obtain UHC's published Takhzyro PA criteria and complete a one-to-one mapping:

| PA Criterion | Chart / Documentation Response | |---|---| | HAE diagnosis confirmed by [method] | [Genetic or lab report with date] | | Minimum qualifying attack frequency | [Attack log summary] | | Prior prophylactic therapy attempted | [Agent, dates, outcome] | | Prescriber specialty requirement | [Specialty credentials] | | Ongoing treatment need | [Most recent clinical notes] |

Refer to the FDA-approved prescribing information on DailyMed to confirm the approved indication language, and use that exact language in your prescriber's letter to ensure it aligns with both the label and UHC's policy.